{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=49", "query": { "condition": "Ovarian Cancer", "page": 49 }, "page_size": 10 }, "pagination": { "page": 49, "page_size": 10, "total_count": 2465, "total_pages": 247, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=50&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=48&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T01:25:02.734Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00333502", "title": "Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Solid Tumor" ], "interventions": [ { "name": "Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2006-05", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-11-02T01:25:02.734Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Duarte, California • Farmington, New Mexico", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Farmington", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00333502" }, { "nct_id": "NCT00004037", "title": "Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "1998-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-04-11", "last_synced_at": "2026-11-02T01:25:02.734Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 53 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004037" }, { "nct_id": "NCT01372553", "title": "Guilford Genomic Medicine Initiative (GGMI)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Ovarian Cancer", "Colon Cancer", "Thrombophilia" ], "interventions": [], "intervention_types": [], "sponsor": "The Moses H. Cone Memorial Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1184, "start_date": "2009-10", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2014-04-16", "last_synced_at": "2026-11-02T01:25:02.734Z", "location_count": 1, "location_summary": "Greensboro, North Carolina", "locations": [ { "city": "Greensboro", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01372553" }, { "nct_id": "NCT07736937", "title": "Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "TUB-040 + Carbo + BEV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 72, "start_date": "2026-03-30", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-11-02T01:25:02.734Z", "location_count": 3, "location_summary": "Los Angeles, California • East Brunswick, New Jersey • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07736937" }, { "nct_id": "NCT06865677", "title": "Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Platinum Resistant Epithelial Ovarian Carcinoma", "Recurrent Epithelial Endometrial Carcinoma", "Recurrent Epithelial Cervical Carcinoma" ], "interventions": [ { "name": "Sacituzumab Govitecan", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "Brain MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "CT scans", "type": "DIAGNOSTIC_TEST" }, { "name": "Tumor biopsy", "type": "PROCEDURE" }, { "name": "Loperamide", "type": "DRUG" }, { "name": "Octreotide", "type": "DRUG" }, { "name": "Diphenoxylate/Atropine", "type": "DRUG" }, { "name": "Antiemetics", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 2, "start_date": "2025-06-09", "completion_date": "2025-07-01", "has_results": true, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-11-02T01:25:02.734Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06865677" }, { "nct_id": "NCT02155777", "title": "Why do Oral Contraceptives Prevent Ovarian Cancer?", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Ovarian Cancer Risk", "Risk-reducing Surgery", "Fallopian Tube Fimbriae", "Ovarian Cortical Inclusion Cysts" ], "interventions": [ { "name": "OrthoNovum 1/35", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "30 Years to 45 Years · Female only" }, "enrollment_count": 52, "start_date": "2014-06", "completion_date": "2018-06", "has_results": false, "last_update_posted_date": "2020-06-25", "last_synced_at": "2026-11-02T01:25:02.734Z", "location_count": 2, "location_summary": "Los Angeles, California • Ann Arbor, Michigan", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02155777" }, { "nct_id": "NCT02001623", "title": "Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovary Cancer", "Cervix Cancer", "Endometrium Cancer", "Bladder Cancer", "Prostate Cancer (CRPC)", "Esophagus Cancer", "Lung Cancer(NSCLC)", "Squamous Cell Carcinoma of the Head and Neck (SCCHN)" ], "interventions": [ { "name": "Tisotumab Vedotin (HuMax-TF-ADC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 195, "start_date": "2013-11-30", "completion_date": "2019-05-02", "has_results": true, "last_update_posted_date": "2021-12-29", "last_synced_at": "2026-11-02T01:25:02.734Z", "location_count": 8, "location_summary": "Orange, California • New Haven, Connecticut • Miami, Florida + 5 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT02001623" }, { "nct_id": "NCT00951496", "title": "Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Malignant Ovarian Brenner Tumor", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Primary Peritoneal Clear Cell Adenocarcinoma", "Primary Peritoneal Endometrioid Adenocarcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Primary Peritoneal Transitional Cell Carcinoma", "Primary Peritoneal Undifferentiated Carcinoma", "Stage II Fallopian Tube Cancer AJCC v6 and v7", "Stage II Ovarian Cancer AJCC v6 and v7", "Stage IIA Fallopian Tube Cancer AJCC v6 and v7", "Stage IIA Ovarian Cancer AJCC V6 and v7", "Stage IIB Fallopian Tube Cancer AJCC v6 and v7", "Stage IIB Ovarian Cancer AJCC v6 and v7", "Stage IIC Fallopian Tube Cancer AJCC v6 and v7", "Stage IIC Ovarian Cancer AJCC v6 and v7", "Stage III Ovarian Cancer AJCC v6 and v7", "Stage III Primary Peritoneal Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1560, "start_date": "2009-08-11", "completion_date": "2016-01-11", "has_results": true, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-11-02T01:25:02.734Z", "location_count": 503, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 332 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00951496" }, { "nct_id": "NCT00791778", "title": "Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 246, "start_date": "2008-11", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2015-09-28", "last_synced_at": "2026-11-02T01:25:02.734Z", "location_count": 4, "location_summary": "La Jolla, California • Jacksonville, Florida • Augusta, Georgia + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Scarborough", "state": "Maine" } ], "official_url": "https://clinicaltrials.gov/study/NCT00791778" }, { "nct_id": "NCT02517554", "title": "A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Ovarian Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site", "type": "BEHAVIORAL" }, { "name": "Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site", "type": "BEHAVIORAL" }, { "name": "Patient receives written information on how to find genetic services in their area", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2015-08", "completion_date": "2019-11", "has_results": false, "last_update_posted_date": "2024-01-19", "last_synced_at": "2026-11-02T01:25:02.734Z", "location_count": 7, "location_summary": "Elkton, Maryland • Cape May Court House, New Jersey • Sewell, New Jersey + 3 more", "locations": [ { "city": "Elkton", "state": "Maryland" }, { "city": "Cape May Court House", "state": "New Jersey" }, { "city": "Sewell", "state": "New Jersey" }, { "city": "Somers Point", "state": "New Jersey" }, { "city": "Gettysburg", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02517554" } ] }